Loading patent…
AssigneeHadasit Medical Research Services and Development Ltd.
InventorIris Lavon
Estimating the term…
The invention relates to nucleic acid sequences comprising NF-κB binding sites derived from the MGMT promoter region and uses thereof as decoy molecules in the treatment of cancer and immune-related disorders. More particularly, the invention relates to nucleic acid sequences as well as to modified oligonucleotides (ODNs) comprising NF-κB binding sites derived from the MGMT promoter region, and uses thereof as decoy molecules for inhibiting NF-κB enhanced expression of MGMT. The invention further relates to compositions, kits and screening methods using the NF-κB binding sites of the invention or ODNs comprising the same for treating cancer and immune related disorders.
An isolated nucleic acid sequence comprising an NF-κB binding site derived from the O(6)-Methylguanine-DNA-Methyltransferase (MGMT) promoter region, wherein said sequence has the nucleic acid sequence as set forth in any one of SEQ ID NO. 4, 5, 30, 32, 34, 28, 29, 31, 33 and 35.
A construct comprising at least one repeat of a nucleic acid sequence of an NF-κB binding site derived from the MGMT promoter region, wherein said sequence is selected from the nucleic acid sequence as denoted by any one of SEQ ID NO. 4, 5, 30, 32, 34, 28, 29, 31, 33 and 35.
An NF-κB decoy in the form of a double stranded oligonucleotide (ODN) or oligonucleotide analogue comprising at least one repeat of at least one nucleic acid sequence of an NF-κB binding site derived from the MGMT promoter region, wherein said sequence has the nucleic acid sequence as set forth in any one of SEQ ID NO. 4, 5, 30, 32, 34, 28, 29, 31, 33 and 35.
A composition comprising as an active ingredient an effective amount of at least one NF-κB decoy in the form of an oligonucleotide (ODN) or oligonucleotide analogue comprising at least one repeat of at least one nucleic acid sequence of an NF-κB binding site derived from the MGMT promoter region, wherein said sequence has the nucleic acid sequence as denoted by any one of SEQ ID NO. 4, 5, 30, 32, 34, 28, 29, 31, 33 and 35.
Dependencies are inferred from the claim text.